Several outlets are highlighting key FDA decisions expected in the third quarter of 2026, with a focus on oncology. However, reports also indicate uncertainty surrounding the FDA due to a leadership change. The exact number and nature of the decisions to be made are not consistent across reports, with some outlets referencing different timeframes or numbers of anticipated decisions.